'Molecular targets' presentation slideshows

1.04k views • 56 slides

578 views • 37 slides

Discovery and Molecular Targets

Discovery and Molecular Targets. Susan Holbeck, Ph.D. National Cancer Institute Developmental Therapeutics Program Information Technology Branch holbecks@mail.nih.gov. NCI-DTP Drug Discovery Resources. NCI panel of 60 human tumor cell lines 2 day 5-dose growth inhibition assay

570 views • 32 slides

Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P

CTOS-Seattle, November 2007. TERAPEUTIC CONSEQUENCES FROM MOLECOLAR BIOLOGY FOR GIST PATIENTS AFFECTED BY NEUROFIBROMATOSIS TYPE 1. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Mannheim University Hospital, Germany Bonn University Hospital, Germany

432 views • 32 slides

Joint FAO/WHO Workshop on fruit and vegetables Aug. 15, 2006. Coex, Seoul

Joint FAO/WHO Workshop on fruit and vegetables Aug. 15, 2006. Coex, Seoul. Production and consumption of horticultural products in Korea and cancer chemopreventive activity of fruit and vegetables.

409 views • 29 slides

Joshua Ko School of Chinese Medicine Hong Kong Baptist University

Herbal diterpenoids pseudolaric acid B and triptolide induce growth arrest and apoptosis in colon cancer cells. Joshua Ko School of Chinese Medicine Hong Kong Baptist University. Pseudolaric acid B. Introduction.

435 views • 27 slides

Managing Gastrointestinal Side Effects of Targeted Therapies

Managing Gastrointestinal Side Effects of Targeted Therapies. Amy Goodrich, MSN, NP-AC The Johns Hopkins Kimmel Cancer Center, Baltimore, MD. General Concepts of GI Toxicity in Cancer Patients.

493 views • 22 slides

R&I: Ovarian Cancer Therapeutics in Major Developed Markets

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. Detailed report at: http://www.reportsandintelligence.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market

283 views • 10 slides

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifyin

223 views • 10 slides

R&I: Psoriasis - Identifying and Commercializing Market

Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Detailed report at: http://www.reportsandintelligence.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market

266 views • 9 slides

Frontier:Alzheimers Disease-Identifying Market

Big Market Research presents this report which covers and includes a brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms,the changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline Read The Complete Report On : http://www.bigmarketresearch.com/frontier-pharma-alzheimers-disease-identifying-and-commercializing-first-in-class-innovation-market

222 views • 9 slides

Transplantation therapeutics Global Market Forecast

Frontier Pharma: Transplantation Therapeutics-A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

95 views • 9 slides

Liver Cancer-Identifying and Commercializing First-in-Class

The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market

265 views • 8 slides

Multiresistances and Pathogeny factors from Nematodes

Loire Valley Research Center UMR 1282 - ISP. Multiresistances and Pathogeny factors from Nematodes. Our main research topics. Identification of the molecular targets of AH () in nematodes old and new molecules Decipher the molecular mechanisms involved in AH resistance

72 views • 7 slides

Psoriasis - Identifying and Commercializing First-in-Class I

168 views • 6 slides

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation - Market overview, size, outlook, g

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

155 views • 6 slides

Future Market Trends of Obesity Market Till 2021

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.

130 views • 5 slides

218 views • 5 slides

Table 1 Possible molecular targets and corresponding biologic agents in SLE

Table 1 Possible molecular targets and corresponding biologic agents in SLE. Stohl, W. (2013) Future prospects in biologic therapy for systemic lupus erythematosus Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2013.136.

132 views • 1 slides